Literature DB >> 32289181

Divergent chemokine receptor expression and the consequence for human IgG4 B cell responses.

Peter-Paul A Unger1, Laura C Lighaam1, Ellen Vermeulen1, Simone Kruithof1, Mateusz Makuch1, Emma L Culver2, Robin van Bruggen3, Ester B M Remmerswaal4, Ineke J M Ten Berge4, Reindert W Emmens5, Hans W M Niessen5, Eleanor Barnes2, Gerrit J Wolbink1,6, S Marieke van Ham1,7, Theo Rispens1.   

Abstract

IgG4 antibodies are unique to humans. IgG4 is associated with tolerance during immunotherapy in allergy, but also with pathology, as in pemphigus vulgaris and IgG4-related disease. Its induction is largely restricted to nonmicrobial antigens, and requires repeated or prolonged antigenic stimulation, for reasons poorly understood. An important aspect in generating high-affinity IgG antibodies is chemokine receptor-mediated migration of B cells into appropriate niches, such as germinal centers. Here, we show that compared to IgG1 B cells, circulating IgG4 B cells express lower levels of CXCR3, CXCR4, CXCR5, CCR6, and CCR7, chemokine receptors involved in GC reactions and generation of long-lived plasma cells. This phenotype was recapitulated by in vitro priming of naive B cells with an IgG4-inducing combination of TFH /TH2 cytokines. Consistent with these observations, we found a low abundance of IgG4 B cells in secondary lymphoid tissues in vivo, and the IgG4 antibody response is substantially more short-lived compared to other IgG subclasses in patient groups undergoing CD20+ B cell depletion therapy with rituximab. These results prompt the hypothesis that factors needed to form IgG4 B cells restrain at the same time the induction of a robust migratory phenotype that could support a long-lived IgG4 antibody response.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  B cells; IgG4; chemokine receptors; rituximab; ulcerative colitis

Mesh:

Substances:

Year:  2020        PMID: 32289181     DOI: 10.1002/eji.201948454

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

Review 1.  The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases.

Authors:  Tamsin Cargill; Emma L Culver
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

Review 2.  IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies.

Authors:  Marinos C Dalakas
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-11-29

3.  Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody.

Authors:  Ying Hou; Chao Zhang; Xiaolin Yu; Wenqing Wang; Dong Zhang; Yunfei Bai; Chuanzhu Yan; Lin Ma; Anning Li; Jian Ji; Lili Cao; Qinzhou Wang
Journal:  Front Immunol       Date:  2022-07-26       Impact factor: 8.786

Review 4.  Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.

Authors:  C Zografou; A G Vakrakou; P Stathopoulos
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

Review 5.  Helper T Cells in Idiopathic Membranous Nephropathy.

Authors:  Qihan Zhao; Haoran Dai; Xianli Liu; Hanxue Jiang; Wenbin Liu; Zhendong Feng; Na Zhang; Yu Gao; Zhaocheng Dong; Xiaoshan Zhou; Jieli Du; Naiqian Zhang; Hongliang Rui; Li Yuan; Baoli Liu
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.